BioSpace News Archive

Olympus announced the appointment of Julien Sauvagnargues to the role of President and Chief Executive Officer, Olympus Corporation of the Americas, reporting to Olympus Chief Strategy Officer, Gabriela Kaynor, effective April 1, 2024.

The shareholders of BioInvent International AB, Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 3 May 2024 at Elite Hotel Ideon on Scheelevägen 27 in Lund, Sweden.

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023.

The global clinical microbiology market size was estimated at around USD 4.58 billion in 2023 and it is projected to hit around USD 7.73 billion by 2033.

MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, has released and hosted a conference call regarding its full year and fourth quarter financial results for the period ended December 31, 2023.

According to the latest research by nova one advisor, the global biopharmaceuticals contract manufacturing market size was exhibited at USD 19.89 billion in 2023 and is projected to hit around USD 31.92 billion by 2032, growing at a CAGR of 5.4% during the forecast period 2023 to 2032.

Algernon Pharmaceuticals Inc. is pleased to announce that it has closed on its agreement with Seyltx Inc., a privately owned U.S. based drug development company, for the acquisition of Algernon’s NP-120 research program for the purchase price of USD $2M cash and a 20% common share equity position in Seyltx.

Singapore, 27 March, 2024 - INEX Innovate is excited to share that its groundbreaking product, OvaCis® Rapid Test, has received regulatory approval from the Health Sciences Authority (HSA) in Singapore.

Toronto, Ontario and Calgary, Alberta--(Newsfile Corp. - March 27, 2024) - Biosenta Inc. (CSE: ZRO) (“Biosenta” or the “Company”) is pleased to announce a significant milestone in its technological and operational advancements with the successful construction and operation of a bench scale production plant.

Integral Molecular proudly announces the achievement of IS0 9001 certification for the quality systems and processes used in its Membrane Proteome Array™ specificity testing services.